EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer (Prostate005)
Prospective Trial of Combination External Beam Radiation Therapy and MRI-guided, Dose-differentiated High Dose-rate Prostate Brachytherapy Boost for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
Sponsor: University of Virginia
This observational or N/A phase trial investigates Prostate Adenocarcinoma and Prostate Cancer and is currently ongoing. University of Virginia leads this study, which shows 9 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE2 → None
-
Sep 2024 — Apr 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jun 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2023 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, and overall survival for patients receiving this treatment.
Contact Information
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .